Drugs / huCART-meso
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05057715 | Mar 2022 → Sep 2038 expected | malignant epithelial tumor of ovary, pancreatic adenocarcinoma | University of Pennsylvania | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | huCART-meso | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05057715 ↗ |
| Modality | Cell therapy | “Human Chimeric Antigen Receptor Modified T Cells” NCT05057715 ↗ |
| Route | Intravenous | “Intravenous administration of huCART-meso cells” NCT05057715 ↗ |